Why the study?
Do platelet-activating factor (PAF) antagonists protect cultured human endothelial cells from lysis induced by elastase or activated neutrophils?
Do platelet-activating factor (PAF) antagonists protect cultured human endothelial cells from lysis induced by elastase or activated neutrophils?
PAF receptor antagonists protect human endothelial cells from elastase- and neutrophil-induced lysis in vitro, suggesting a role for PAF in this mechanism of endothelial injury.
Hypothesis-generating for PAF in endothelial injury; leaves open translation to in vivo or clinical settings.
The mechanism(s) responsible for injury of endothelial cells induced by human leukocyte elastase (HLE) was investigated in an immortalized venous human endothelial cell line (IVEC). 2. First, the proteinase concentrations and incubation delays necessary to trigger a significant IVEC cytotoxicity were determined by chromium assays. Thus, exposure of IVEC for 6 h to 10 micrograms ml-1 HLE resulted in 22 +/- 2.8% lysis and 36.4 +/- 5.4% detachment (mean +/- s.e. mean; n = 4; P < 0.05). 3. WEB 2086, a specific platelet-activating factor (PAF) receptor antagonist, induced a significant concentration-dependent decrease of such a lysis (39.6 +/- 7.7% protection at 100 microM; n = 4). This potential role for PAF was confirmed with two other antagonists of this lipid mediator, i.e., BN 52021 and RP 48740. 4. Finally, we demonstrated that pretreatment of IVEC with WEB 2086 protected significantly against cell lysis induced by stimulated human neutrophils, an experimental model in which HLE participates.
No takes yet. Share an insight, caveat, or question.
Renesto et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: